RCT | 4-week course of subcutaneous ketamine shows efficacy in treatment-resistant depression

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial – British Journal of Psychiatry

News Release: Ketamine effective for treatment-resistant depression: Clinical trial – University of New South Wales

Related:

RCT | Ketamine non-Inferiority to ECT for nonpsychotic resistant depression

M-A | Electroconvulsive therapy may be superior to ketamine for patients with major depressive episode

RCT | Assessing low-dose ketamine’s antidepressant & antisuicidal effects in patients with treatment-resistant depression

M-A | Efficacy and safety of ketamine vs. electroconvulsive therapy among patients with major depressive episode.